Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Station 19, CH-1015 Lausanne, Switzerland.
Future Microbiol. 2011 Jun;6(6):617-33. doi: 10.2217/fmb.11.46.
The recent years have witnessed significant progress in the development of new drug candidates for the treatment of TB. While many of these are now in clinical trials, continued research is needed in order to sustain the drug discovery pipeline and meet the increasing needs of TB patients. These include shortening treatment, killing drug-resistant strains, and finding medications compatible with antiretroviral and diabetes therapy. Nowadays, TB drug discovery benefits from high-throughput screening methods, availability of conditional expression systems, and biophysical and biochemical techniques that enable target-based rational drug design. This article reviews the current state of TB drug development and discusses possible approaches to finding new leads.
近年来,新型抗结核候选药物的研发取得了显著进展。虽然其中许多药物已进入临床试验阶段,但仍需继续开展研究,以维持药物研发管线并满足日益增长的结核患者需求。这些需求包括缩短治疗时间、杀灭耐药菌株以及寻找与抗逆转录病毒和糖尿病治疗兼容的药物。如今,结核药物研发受益于高通量筛选方法、条件表达系统的可用性以及能够实现基于靶点的合理药物设计的生物物理和生物化学技术。本文综述了当前结核药物研发的现状,并讨论了寻找新先导化合物的可能方法。